Skip to main navigation Skip to search Skip to main content

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer

  • Yuichiro Doki
  • , Makoto Ueno
  • , Chih Hung Hsu
  • , Do Youn Oh
  • , Keunchil Park
  • , Noboru Yamamoto
  • , Tatsuya Ioka
  • , Hiroki Hara
  • , Manabu Hayama
  • , Masahiro Nii
  • , Keiko Komuro
  • , Mariko Sugimoto
  • , Makoto Tahara
  • The University of Osaka
  • Kanagawa Cancer Center Research Institute
  • National Taiwan University
  • Seoul National University
  • National Cancer Center Japan
  • Osaka International Cancer Institute
  • Saitama Cancer Center
  • AstraZeneca

Research output: Contribution to journal › Article › peer-review

59   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science